Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Все ли ингибиторы ангиотензинпревращающего фермента одинаковы? Фокус на зофеноприл
Все ли ингибиторы ангиотензинпревращающего фермента одинаковы? Фокус на зофеноприл
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Проанализированы результаты рандомизированных клинических испытаний. Показано, что назначение ингибитора ангиотензин-превращающего фермента зофеноприла больным сердечно-сосудистыми заболеваниями ведет к снижению риска сердечно-сосудистых осложнений и смертности. Отмечено, что зофеноприл безопасен и хорошо переносится больными.
Ключевые слова: артериальная гипертензия, ИАПФ, зофеноприл
Key words: arterial hypertension, ACE inhibitors, zofenopril
Ключевые слова: артериальная гипертензия, ИАПФ, зофеноприл
________________________________________________
Key words: arterial hypertension, ACE inhibitors, zofenopril
Полный текст
Список литературы
1. Turnbull F, Neal B, Algert C et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165: 1410–9.
2. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
4. Singhvi SM, Foley JE, Willard DA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970–3.
5. Marzo A, Dal Bo L, Mazzucchelli P. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittel-Forsch 1999; 49: 992–6.
6. Meredith PA, Elliott HL. ACE inhibition and 24 hour control of blood pressure. SP Scienze Press 2001 (accepted for publication).
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
8. Мак T, Freedman AM, Dickens BF, Weglicki WB. Protective effets of sulfhy-dryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169–75.
9. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin converting enzym inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardiopro-tection. J Pharmacol Exp Ther 1991; 257: 919–29.
10. Chopra M, Beswick H, Clapperton M et al. An-tioxidant effects of angiotensin converting enzyme inhibitors: free radicals and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and non sulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330–40.
11. Ferrari R, Cargnoni A, Curello S et al. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insights into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Aiming PB, Grocott-Mason RM, Lewis MJ. Effects of sulfhydryl and non sulfhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated heart. Endothelium 1997; 5: 265–75.
13. Buikema H, Monnink SH, Tio RA et al. Comparison of zofinopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999–2000.
14. Cleophas TJ, Van Ouwerkerk B, Van der Meulen J et al. Lercanidipine in patients with hypertension and diabetes II. Angiology 2001; 52: 469–75.
15. Soriano JB, Ferro A, Wilhelmi E. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 93: 445–56.
16. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharm Res 1992; 9: 1480–6.
17. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme inhibitors by their selective inhibitions of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–306.
18. Sun Y, Mendelsohn АО. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478–86.
19. Tio R, de Langen C, de Graef P et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 1990; 4: 695–704.
20. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
21. Mallion J-M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 13–8.
22. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 16 (Suppl. 2): 7–12.
23. Borghi C, Bacchelli S, Esposti DD et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Exp Opin Pharmacother 2004; 5 (9): 1965–77.
24. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
25. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press.2007; 16 (Suppl. 2): 19–24.
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232.
27. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 25–30.
28. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16: 1–6.
29. Pfeffer M, Pfeffer I. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388–90.
30. Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–41.
31. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
32. Ambrosioni Е, Borghi С, Magnani В et аl. for the Surviva1 of Myocardial Infinctiоn Long-Тerm Eva1uation (SМILE) Study Investigators. The effect of the angiotensin-converting еnzymе inhibitor zofenopril оn mortality and morbidity after anterior myocanlia1 infarctiоn. New Engl J Med 1995; 332: 80–5.
2. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
4. Singhvi SM, Foley JE, Willard DA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970–3.
5. Marzo A, Dal Bo L, Mazzucchelli P. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittel-Forsch 1999; 49: 992–6.
6. Meredith PA, Elliott HL. ACE inhibition and 24 hour control of blood pressure. SP Scienze Press 2001 (accepted for publication).
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
8. Мак T, Freedman AM, Dickens BF, Weglicki WB. Protective effets of sulfhy-dryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169–75.
9. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin converting enzym inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardiopro-tection. J Pharmacol Exp Ther 1991; 257: 919–29.
10. Chopra M, Beswick H, Clapperton M et al. An-tioxidant effects of angiotensin converting enzyme inhibitors: free radicals and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and non sulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330–40.
11. Ferrari R, Cargnoni A, Curello S et al. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insights into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Aiming PB, Grocott-Mason RM, Lewis MJ. Effects of sulfhydryl and non sulfhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated heart. Endothelium 1997; 5: 265–75.
13. Buikema H, Monnink SH, Tio RA et al. Comparison of zofinopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999–2000.
14. Cleophas TJ, Van Ouwerkerk B, Van der Meulen J et al. Lercanidipine in patients with hypertension and diabetes II. Angiology 2001; 52: 469–75.
15. Soriano JB, Ferro A, Wilhelmi E. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 93: 445–56.
16. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharm Res 1992; 9: 1480–6.
17. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme inhibitors by their selective inhibitions of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–306.
18. Sun Y, Mendelsohn АО. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478–86.
19. Tio R, de Langen C, de Graef P et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 1990; 4: 695–704.
20. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
21. Mallion J-M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 13–8.
22. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 16 (Suppl. 2): 7–12.
23. Borghi C, Bacchelli S, Esposti DD et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Exp Opin Pharmacother 2004; 5 (9): 1965–77.
24. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
25. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press.2007; 16 (Suppl. 2): 19–24.
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232.
27. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 25–30.
28. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16: 1–6.
29. Pfeffer M, Pfeffer I. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388–90.
30. Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–41.
31. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
32. Ambrosioni Е, Borghi С, Magnani В et аl. for the Surviva1 of Myocardial Infinctiоn Long-Тerm Eva1uation (SМILE) Study Investigators. The effect of the angiotensin-converting еnzymе inhibitor zofenopril оn mortality and morbidity after anterior myocanlia1 infarctiоn. New Engl J Med 1995; 332: 80–5.
2. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
4. Singhvi SM, Foley JE, Willard DA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970–3.
5. Marzo A, Dal Bo L, Mazzucchelli P. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittel-Forsch 1999; 49: 992–6.
6. Meredith PA, Elliott HL. ACE inhibition and 24 hour control of blood pressure. SP Scienze Press 2001 (accepted for publication).
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
8. Мак T, Freedman AM, Dickens BF, Weglicki WB. Protective effets of sulfhy-dryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169–75.
9. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin converting enzym inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardiopro-tection. J Pharmacol Exp Ther 1991; 257: 919–29.
10. Chopra M, Beswick H, Clapperton M et al. An-tioxidant effects of angiotensin converting enzyme inhibitors: free radicals and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and non sulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330–40.
11. Ferrari R, Cargnoni A, Curello S et al. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insights into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Aiming PB, Grocott-Mason RM, Lewis MJ. Effects of sulfhydryl and non sulfhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated heart. Endothelium 1997; 5: 265–75.
13. Buikema H, Monnink SH, Tio RA et al. Comparison of zofinopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999–2000.
14. Cleophas TJ, Van Ouwerkerk B, Van der Meulen J et al. Lercanidipine in patients with hypertension and diabetes II. Angiology 2001; 52: 469–75.
15. Soriano JB, Ferro A, Wilhelmi E. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 93: 445–56.
16. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharm Res 1992; 9: 1480–6.
17. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme inhibitors by their selective inhibitions of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–306.
18. Sun Y, Mendelsohn АО. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478–86.
19. Tio R, de Langen C, de Graef P et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 1990; 4: 695–704.
20. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
21. Mallion J-M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 13–8.
22. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 16 (Suppl. 2): 7–12.
23. Borghi C, Bacchelli S, Esposti DD et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Exp Opin Pharmacother 2004; 5 (9): 1965–77.
24. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
25. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press.2007; 16 (Suppl. 2): 19–24.
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232.
27. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 25–30.
28. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16: 1–6.
29. Pfeffer M, Pfeffer I. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388–90.
30. Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–41.
31. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
32. Ambrosioni Е, Borghi С, Magnani В et аl. for the Surviva1 of Myocardial Infinctiоn Long-Тerm Eva1uation (SМILE) Study Investigators. The effect of the angiotensin-converting еnzymе inhibitor zofenopril оn mortality and morbidity after anterior myocanlia1 infarctiоn. New Engl J Med 1995; 332: 80–5.
________________________________________________
2. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64.
3. Turnbull F. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
4. Singhvi SM, Foley JE, Willard DA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970–3.
5. Marzo A, Dal Bo L, Mazzucchelli P. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittel-Forsch 1999; 49: 992–6.
6. Meredith PA, Elliott HL. ACE inhibition and 24 hour control of blood pressure. SP Scienze Press 2001 (accepted for publication).
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
8. Мак T, Freedman AM, Dickens BF, Weglicki WB. Protective effets of sulfhy-dryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169–75.
9. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin converting enzym inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardiopro-tection. J Pharmacol Exp Ther 1991; 257: 919–29.
10. Chopra M, Beswick H, Clapperton M et al. An-tioxidant effects of angiotensin converting enzyme inhibitors: free radicals and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and non sulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330–40.
11. Ferrari R, Cargnoni A, Curello S et al. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insights into its mechanism of action. J Cardiovasc Pharmacol 1992; 20: 694–704.
12. Aiming PB, Grocott-Mason RM, Lewis MJ. Effects of sulfhydryl and non sulfhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated heart. Endothelium 1997; 5: 265–75.
13. Buikema H, Monnink SH, Tio RA et al. Comparison of zofinopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999–2000.
14. Cleophas TJ, Van Ouwerkerk B, Van der Meulen J et al. Lercanidipine in patients with hypertension and diabetes II. Angiology 2001; 52: 469–75.
15. Soriano JB, Ferro A, Wilhelmi E. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 93: 445–56.
16. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharm Res 1992; 9: 1480–6.
17. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme inhibitors by their selective inhibitions of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–306.
18. Sun Y, Mendelsohn АО. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478–86.
19. Tio R, de Langen C, de Graef P et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 1990; 4: 695–704.
20. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
21. Mallion J-M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 13–8.
22. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 16 (Suppl. 2): 7–12.
23. Borghi C, Bacchelli S, Esposti DD et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Exp Opin Pharmacother 2004; 5 (9): 1965–77.
24. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
25. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press.2007; 16 (Suppl. 2): 19–24.
26. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232.
27. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 25–30.
28. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16: 1–6.
29. Pfeffer M, Pfeffer I. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388–90.
30. Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–41.
31. Ambrosioni Е, Borghi С, Маgnani В. Survival of mуосardiаl infarction long-term eva1uation (SМILE) study: rationale, design, organization, and outcome definitions. Control Сlin Trials 1994; 15 (3): 201–10.
32. Ambrosioni Е, Borghi С, Magnani В et аl. for the Surviva1 of Myocardial Infinctiоn Long-Тerm Eva1uation (SМILE) Study Investigators. The effect of the angiotensin-converting еnzymе inhibitor zofenopril оn mortality and morbidity after anterior myocanlia1 infarctiоn. New Engl J Med 1995; 332: 80–5.
Авторы
Л.Г.Ратова*, И.Е.Чазова
ФГУ Российский кардиологический научно-производственный комплекс, НИИ кардиологии им. А.Л.Мясникова, Москва
*lratova@mail.ru
FSI Russian cardiology scientific and production complex, Moscow
*lratova@mail.ru
ФГУ Российский кардиологический научно-производственный комплекс, НИИ кардиологии им. А.Л.Мясникова, Москва
*lratova@mail.ru
________________________________________________
FSI Russian cardiology scientific and production complex, Moscow
*lratova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.